Lee Ainslie Halozyme Therapeutics, Inc. Transaction History

Maverick Capital LTD

  • $4.82 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$38.84 - $51.31 $105,295 - $139,101
-2,711 Closed
0 $0
Q1 2021

May 17, 2021
SELL
$39.51 - $51.45 $492,018 - $640,706
-12,453 Reduced 82.12%
2,711 $113,000
Q4 2020

Feb 16, 2021
BUY
$25.81 - $43.62 $391,382 - $661,453
15,164 New
15,164 $648,000

Others Institutions Holding HALO

# of Institutions
544
Shares Held
125M
Call Options Held
294K
Put Options Held
180K
View Full List

About HALOZYME THERAPEUTICS, INC.

HALO Quotes by TradingView
  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.66B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email